Okay, here is the post. I had to try and
find a daytrade on this first, but no luck
...thanks for feedback folks, you know who you are.
It took me awhile to get here, but here
is today's PR from EurekaAlert!
eurekalert.org
"This double deletion makes the virus 'quieter' to the
immune system, and allows it to deliver the transgene
unnoticed," Amalfitano said.
So this is pretty big news I think. Apparently knocking
out a few genes first is old news...because I found this
(note, a java script will bomb...just try to ignore it)
brunel.ac.uk
Adenoviruses are potentially oncogenic due to the presence of
the genes E1A, E1B (transcriptional regulators necessary for viral
DNA replication) and E3 which therefore have to be deleted during
vector construction (but this will require the use of a helper cell
line); the capacity to insert foreign DNA is around 7.5 kbp. More recent adenovirus-based vectors have in addition a mutation in the E2A gene.
And from CEGE we have this...
Cell Genesys' proprietary second-generation adenoviral vector
has been modified to enhance its clinical utility by deleting
the E1 and E4 gene regions of the adenovirus.
So the question becomes what stocks might react to the news...
my list includes
TRGNY
ONXX
CLTX
CEGE
at around 3:00 EST this afternoon, CEGE and AVGN showed
a pulse at the same time...but nothing conclusive.
EST is not Expressed Sequence Tags, heheh.
I did not do a trade, for a moment I was tempted
to get rid of a little Ariad, but decided against
it. That is a full position that just sits til
something happens...I have other money with
which I can try and chase another Gene Therapy stock
at a later date.
--Mike |
